/ANGN
ANGN Stock - Angion Biomedica Corp.
Healthcare|BiotechnologyNASDAQ
$1.00+0.00%
+$0.00 (+0.00%) • Jun 1
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.5
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.96
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+50.0%upside
Target: $1.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ANGN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.99 – $1.01
TARGET (TP)$1.50
STOP LOSS$0.92
RISK/REWARD1:6.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.60
52W High$20.40
52W Low$1.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | $2.30M | $28.31M | $2.88M | $1.49M |
| Gross Profit | N/A | $2.30M | $27.88M | $1.69M | $847,000 |
| Gross Margin | N/A | 100.0% | 98.5% | 58.7% | 57.0% |
| Operating Income | $-44,986,000 | $-30,436,000 | $-39,307,000 | $-55,273,000 | $-38,591,000 |
| Net Income | $-51,898,000 | $-55,700,000 | $-53,772,000 | $-79,479,000 | $-42,365,000 |
| Net Margin | N/A | -2420.7% | -189.9% | -2759.7% | -2849.0% |
| EPS | $-4.25 | $-1.85 | $-1.90 | $-2.76 | $-2.51 |
Company Overview
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ANGNBeat Rate
63%
Last 8 quarters
Avg Surprise
-49.5%
EPS vs Estimate
Beats / Misses
5/3
Last 12 quarters
Latest EPS
$-1.27
Q4 2023
EPS Surprise History
Q4 21
No data
Q2 22
-9.1%
$-0.48vs$-0.44
Q3 22
+34.8%
$-0.30vs$-0.46
Q4 22
+41.7%
$-0.21vs$-0.36
Q4 22
No data
Q2 23
+72.2%
$-0.15vs$-0.54
Q3 23
-527.7%
$-2.44vs$0.57
Q4 23
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | May 8, 2024 | — | — | — | — |
Q4 2023 | Nov 13, 2023 | — | $-1.27 | — | — |
Q3 2023 | Aug 21, 2023 | $0.57 | $-2.44 | -527.7% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-0.54 | $-0.15 | +72.2% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | — | $-0.38 | — | — |
Q4 2022 | Nov 14, 2022 | $-0.36 | $-0.21 | +41.7% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.46 | $-0.30 | +34.8% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-0.44 | $-0.48 | -9.1% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $0.44 | — | — |
Q4 2021 | Nov 12, 2021 | $-0.73 | $-0.53 | +27.4% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.69 | $-0.58 | +15.9% | ✓ BEAT |
Q2 2021 | May 17, 2021 | $-0.62 | $-0.94 | -51.6% | ✗ MISS |
Q4 2020 | Dec 31, 2020 | — | $-1.00 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-1.05 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-1.20 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.78 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.95 | — | — |
Q2 2014 | Jun 30, 2014 | — | $-0.02 | — | — |
Q1 2014 | Mar 31, 2014 | — | $-0.02 | — | — |
Q2 2013 | Jun 30, 2013 | — | $0.03 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ANGN
What is ANGN's current stock price?
Angion Biomedica Corp. (ANGN) is currently trading at $1.00 per share. The stock has moved +0.00% today.
What is the analyst price target for ANGN?
The average analyst price target for ANGN is $1.50, based on 1 analyst.
What sector is Angion Biomedica Corp. in?
Angion Biomedica Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ANGN's market cap?
Angion Biomedica Corp. has a market capitalization of $0.03 billion, making it a small-cap company.
Does ANGN pay dividends?
No, Angion Biomedica Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALNA
Allena Pharmaceuticals, Inc.
$0.07
0AMHV
American Hemp Ventures, Inc.
$0.98
Mkt Cap: $0.0B
CHRO
Channel Therapeutics Corporation
$1.35
Mkt Cap: $0.0B
CWBR
CohBar, Inc.
$0.41
Mkt Cap: $0.0B
EMMLF
OKYO Pharma Limited
$0.01
Mkt Cap: $0.0B
MRNS
Marinus Pharmaceuticals, Inc.
$0.55
Mkt Cap: $0.0B
NVIV
InVivo Therapeutics Holdings Corporation
$0.32
Mkt Cap: $0.0B
OMGA
Omega Therapeutics, Inc.
$0.14
Mkt Cap: $0.0B
SER
Serina Therapeutics, Inc.
$2.75
Mkt Cap: $0.0B
VYNT
Vyant Bio, Inc.
$0.19
0Explore stocks similar to ANGN for comparison